Skip to main content
. Author manuscript; available in PMC: 2011 Nov 1.
Published in final edited form as: Curr Opin Hematol. 2010 Nov;17(6):493–499. doi: 10.1097/MOH.0b013e32833eaf1b

Figure 2. The relationship between HLA mismatch and outcome of mini-haploBMT with posttransplantation Cy.

Figure 2

Outcomes (relapse and non-relapse mortality) according to donor-recipient HLA-mismatch (A)(B). Event-free survival according to the number of antigen mismatches (C) (D).

Adapted with permission from: Greater HLA Disparity Is Associated with Reduced Risk of Relapse and Improved Event-Free Survival after Nonmyeloablative, HLA-Haploidentical BMT with Post-Transplantation High-Dose Cyclophosphamide; Yvette L. Kasamon, Mary S. Leffell, Jeanne Kowalski et al; Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 150.